BioCentury | Jan 13, 2021
Finance

IPO filing reveals details of Sana’s deep pipeline, aggregation of next-generation gene and cell therapy technologies

...cardiomyocytes to treat heart failure.Sana acquired glial progenitor cell engineering technology via its purchase of University of Rochester...
BioCentury | Dec 6, 2019
Clinical News

Biogen Alzheimer’s data won’t sway believers or doubters either way

...into impacts that are relevant to patients and their caregivers. He is director of the University of Rochester’s...
BioCentury | Nov 26, 2019
Politics & Policy

Pioneering FDA commissioner Frank Young dies at 88

...trained in pathology, served as Dean of the School of Medicine and Dentistry at the University of Rochester...
BioCentury | Oct 26, 2019
Product Development

If approved, aducanumab will still have hills to climb

...Biogen’s hypothesis was plausible, they’d like to see more data. Porsteinsson is director of the University of Rochester’s...
BioCentury | Oct 23, 2019
Clinical News

Biogen’s aducanumab pleases investors, confounds doctors

...strong and the effect size is consequential,” Porsteinsson told BioCentury. He is director of the University of Rochester’s...
BioCentury | Mar 30, 2018
Product Development

Perception into pain

...University of Rochester Robert Dworkin, a professor of anesthesiology and perioperative medicine, neurology and psychiatry at the University of Rochester...
...number of arms you can in your trial. Ideally two, and perhaps three.” Robert Dworkin, University of Rochester...
...OTCQB:OPNT), Santa Monica, Calif. Trevena Inc. (NASDAQ:TRVN), King of Prussia, Pa. Tufts University, Medford, Mass. University of Rochester...
BioCentury | Oct 18, 2017
Translation in Brief

Predicting Parkinson’s progression

...A team from GNS Healthcare Inc. and the University of Rochester has demonstrated that two SNPs may be...
...when aggressive treatment is appropriate. According to both Khalil and Charles Venuto, assistant professor at University of Rochester...
...Parkinson’s disease: a longitudinal cohort study and validation.” Lancet Neurology (2017) Winnie Pong, Staff Writer GNS Healthcare Inc. University of Rochester Alpha...
BioCentury | Nov 30, 2016
Distillery Therapeutics

Cardiovascular

...2016 doi:10.1073/pnas.1607728113 CONTACT: Chen Yan, University of Rochester School of Medicine and Dentistry, Rochester, N.Y. email: Chen_Yan@URMC.Rochester.edu Steven Hochhauser University of Rochester Phosphodiesterase...
BioCentury | Sep 3, 2015
Targets & Mechanisms

Low-fat brain

...is a known risk marker for the disease; and last year, a team from the University of Rochester...
...N.Y. University of Montreal, Montreal, Quebec University of Montreal Hospital Research Center (CRCHUM), Montreal, Quebec University of Rochester...
BioCentury | Jul 20, 2015
Company News

University of Rochester, Vivione deal

...option period, Vivione and the university will expand on existing data to support clinical testing. University of Rochester...
Items per page:
1 - 10 of 132
BioCentury | Jan 13, 2021
Finance

IPO filing reveals details of Sana’s deep pipeline, aggregation of next-generation gene and cell therapy technologies

...cardiomyocytes to treat heart failure.Sana acquired glial progenitor cell engineering technology via its purchase of University of Rochester...
BioCentury | Dec 6, 2019
Clinical News

Biogen Alzheimer’s data won’t sway believers or doubters either way

...into impacts that are relevant to patients and their caregivers. He is director of the University of Rochester’s...
BioCentury | Nov 26, 2019
Politics & Policy

Pioneering FDA commissioner Frank Young dies at 88

...trained in pathology, served as Dean of the School of Medicine and Dentistry at the University of Rochester...
BioCentury | Oct 26, 2019
Product Development

If approved, aducanumab will still have hills to climb

...Biogen’s hypothesis was plausible, they’d like to see more data. Porsteinsson is director of the University of Rochester’s...
BioCentury | Oct 23, 2019
Clinical News

Biogen’s aducanumab pleases investors, confounds doctors

...strong and the effect size is consequential,” Porsteinsson told BioCentury. He is director of the University of Rochester’s...
BioCentury | Mar 30, 2018
Product Development

Perception into pain

...University of Rochester Robert Dworkin, a professor of anesthesiology and perioperative medicine, neurology and psychiatry at the University of Rochester...
...number of arms you can in your trial. Ideally two, and perhaps three.” Robert Dworkin, University of Rochester...
...OTCQB:OPNT), Santa Monica, Calif. Trevena Inc. (NASDAQ:TRVN), King of Prussia, Pa. Tufts University, Medford, Mass. University of Rochester...
BioCentury | Oct 18, 2017
Translation in Brief

Predicting Parkinson’s progression

...A team from GNS Healthcare Inc. and the University of Rochester has demonstrated that two SNPs may be...
...when aggressive treatment is appropriate. According to both Khalil and Charles Venuto, assistant professor at University of Rochester...
...Parkinson’s disease: a longitudinal cohort study and validation.” Lancet Neurology (2017) Winnie Pong, Staff Writer GNS Healthcare Inc. University of Rochester Alpha...
BioCentury | Nov 30, 2016
Distillery Therapeutics

Cardiovascular

...2016 doi:10.1073/pnas.1607728113 CONTACT: Chen Yan, University of Rochester School of Medicine and Dentistry, Rochester, N.Y. email: Chen_Yan@URMC.Rochester.edu Steven Hochhauser University of Rochester Phosphodiesterase...
BioCentury | Sep 3, 2015
Targets & Mechanisms

Low-fat brain

...is a known risk marker for the disease; and last year, a team from the University of Rochester...
...N.Y. University of Montreal, Montreal, Quebec University of Montreal Hospital Research Center (CRCHUM), Montreal, Quebec University of Rochester...
BioCentury | Jul 20, 2015
Company News

University of Rochester, Vivione deal

...option period, Vivione and the university will expand on existing data to support clinical testing. University of Rochester...
Items per page:
1 - 10 of 132